June 23, 2021 — A decade-long study of the most common forearm fracture in older adults revealed that personalized medicine catering to a patient’s individual needs and environment, not age or X-rays, should guide treatment options.

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare showcased new molecular imaging products and solutions as well as new opportunities to expand access to radioactive tracers and other pharmaceutical imaging agents.

June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, announced the signing of a Master Supply Agreement for the therapeutic radioisotope

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer. Approved by the U.S.

June 21, 2021 — FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, announced the launch of the Persona RF PREMIUM in the United States.

June 18, 2021—While clinician burnout following the COVID-19 pandemic has been widely documented, a recent survey of independent physicians across California, conducted by 

June 18, 2021 — Elekta announced that its Elekta Harmony radiation therapy system recently received U.S. FDA 510(k) clearance, paving the way for U.S. clinics to harness the system to treat a comprehensive range of indications using the latest radiotherapy techniques. Harmony perfectly balances productivity and precision without compromise, making the system well-suited to address changing U.S. demographics and practice patterns.

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now